Ind-Swift Laboratories Ltd

₹ 163 2.77%

12 Jun - close price

indswiftlabs.com BSE: 532305 NSE: INDSWFTLAB

About

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals^[1]

Key Points

Business Overview:^[1]
ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development.
Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.

Website BSE NSE

Market Cap ₹ 1,418 Cr.
Current Price ₹ 163
High / Low ₹ 174 / 87.0
Stock P/E 28.6
Book Value ₹ 159
Dividend Yield 0.00 %
ROCE 4.70 %
ROE 3.87 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 1.02 times its book value
Company is expected to give good quarter
Promoter holding has increased by 3.49% over last quarter.

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of -6.37% over past five years.
Company has a low return on equity of 6.65% over last 3 years.
Earnings include an other income of Rs.36.0 Cr.
Working capital days have increased from 95.7 days to 165 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	304	310	290	288	529	33	12	129	138	153	153	151	170
	241	250	224	236	437	43	24	135	147	149	151	147	149
Operating Profit	64	60	66	52	91	-10	-12	-7	-9	4	1	4	21
OPM %	21%	19%	23%	18%	17%	-29%	-99%	-5%	-7%	2%	1%	3%	12%
	-16	6	7	7	458	11	13	16	220	15	18	22	-3
Interest	22	20	21	21	3	0	0	10	-27	1	2	1	-2
Depreciation	9	14	13	14	20	0	0	6	7	7	7	9	8
Profit before tax	16	32	39	24	527	1	1	-7	230	10	10	16	12
Tax %	255%	45%	18%	19%	6%	-3%	31%	-16%	4%	17%	22%	42%	-26%
	-25	17	32	19	494	1	0	-5	222	9	8	10	15
EPS in Rs	-4.25	2.92	5.36	3.29	83.55	0.16	0.07	-0.93	36.67	1.45	0.98	1.17	1.74
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	660	653	716	765	757	780	891	1,039	1,207	1,709	562	641
	571	546	610	631	630	635	709	837	978	1,403	581	596
Operating Profit	89	107	106	134	126	144	183	202	229	306	-19	45
OPM %	13%	16%	15%	18%	17%	19%	21%	19%	19%	18%	-3%	7%
	-31	1	15	16	120	33	23	37	7	476	305	36
Interest	117	106	88	28	92	107	100	96	92	104	3	1
Depreciation	84	85	88	87	104	90	87	131	57	80	24	31
Profit before tax	-143	-83	-55	36	50	-20	18	13	87	598	258	49
Tax %	-17%	-29%	-29%	39%	42%	7%	117%	117%	45%	10%	3%	16%
	-119	-59	-39	22	29	-21	-3	-2	48	539	250	41
EPS in Rs	-29.14	-14.33	-8.75	4.85	6.09	-3.59	-0.53	-0.36	8.06	91.18	41.32	4.77
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	0%
5 Years:	-6%
3 Years:	-19%
TTM:	14%

Compounded Profit Growth
10 Years:	12%
5 Years:	78%
3 Years:	-7%
TTM:	2695%

Stock Price CAGR
10 Years:	15%
5 Years:	7%
3 Years:	31%
1 Year:	50%

Return on Equity
10 Years:	3%
5 Years:	6%
3 Years:	7%
Last Year:	4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	42	42	45	46	48	60	60	60	60	67	69	87
Reserves	553	476	486	507	540	581	544	541	622	745	1,104	1,297
	1,413	1,457	1,242	1,083	1,148	1,031	1,005	953	862	217	41	18
	236	240	364	387	188	198	210	247	280	432	224	271
Total Liabilities	2,244	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,460	1,438	1,673
	1,117	1,099	1,042	934	914	843	753	630	587	192	273	306
CWIP	113	78	70	69	20	11	19	10	8	51	0	10
Investments	18	18	18	18	19	17	36	29	30	112	213	248
	997	1,020	1,007	1,002	972	998	1,011	1,131	1,199	1,106	952	1,110
Total Assets	2,244	2,215	2,138	2,023	1,924	1,870	1,818	1,801	1,824	1,460	1,438	1,673

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	98	79	96	73	-64	125	135	150	195	-187	-25	-70
	-35	-29	-31	-17	-12	-9	-10	5	-13	-28	-110	-73
	-64	-48	-69	-62	100	-133	-124	-141	-186	657	69	142
Net Cash Flow	-1	3	-4	-6	23	-17	1	14	-4	443	-66	-1
Free Cash Flow	59	49	63	52	-79	114	131	137	182	-250	-51	-156
CFO/OP	111%	74%	90%	54%	-51%	87%	74%	74%	85%	-61%	131%	-140%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	215	208	182	194	169	186	177	160	153	67	107	113
Inventory Days	312	368	305	291	284	315	301	288	242	31	145	191
Days Payable	120	137	91	118	114	124	111	118	113	122	140	188
Cash Conversion Cycle	407	439	396	367	339	377	367	330	282	-24	112	116
Working Capital Days	141	-26	-97	-49	217	248	253	253	234	7	115	165
ROCE %	1%	2%	2%	4%	4%	5%	7%	7%	13%	21%	1%	5%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Dec 2025

R&D Expenditure as percentage of Sales
% ・Standalone data

x.xx	x.xx	x.xx	x.xx	x.xx		x.xx	x.xx	x.xx	x.xx	x.xx
x,xxx	x,xxx	x,xxx		x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	xx	x,xxx
xxx	xxx			xxx						xxx
xxx.xx			xxx.xx		xxx.xx			x,xxx.xx
		xxx.xx	xxx.xx				xxx.xx	xxx.xx
		xxx.xx	xxx.xx				xxx.xx	xxx.xx
								xx		xx
								xx.xx
										xxx
										xx
										xxx
										x,xxx
										x,xxx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Total Team Size / Employees
Number ・Standalone data

DMFs Filed
Number ・Standalone data

Installed Capacity (Bulk Drug/API)
Metric Tonnes (MT) ・Standalone data

Production Volume
Metric Tonnes (MT) ・Standalone data

Sales Volume
Metric Tonnes (MT) ・Standalone data

Global Presence (Countries)
Number ・Standalone data

Capacity Utilization
% ・Standalone data

Global Product Approvals / Registrations
Number ・Standalone data

Installed Capsule Capacity
Million/Annum ・Standalone data

Installed Sachet Capacity
Million/Annum ・Standalone data

Installed Tablet Capacity
Million/Annum ・Standalone data

Total Dossiers Filed
Number ・Standalone data

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

18 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	42.01%	40.94%	40.94%	39.49%	39.49%	43.00%
	0.08%	0.17%	0.31%	0.26%	1.27%	0.65%	0.46%	3.07%	4.27%	14.80%	14.33%	13.88%
	19.49%	19.49%	18.73%	8.03%	0.94%	0.94%	0.94%	0.91%	0.91%	0.68%	0.68%	0.00%
	38.44%	38.34%	38.96%	49.72%	55.81%	56.41%	56.61%	55.08%	53.88%	45.02%	45.50%	43.14%
No. of Shareholders	22,962	25,405	24,633	22,439	25,461	28,883	28,752	28,117	28,709	43,780	42,121	39,222

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	55.46%	54.80%	52.16%	42.00%	42.00%	42.00%	42.01%	42.01%	40.94%	43.00%
	2.27%	0.77%	0.60%	0.28%	0.17%	0.06%	0.00%	0.26%	3.07%	13.88%
	0.00%	0.00%	3.78%	19.50%	19.49%	19.49%	19.49%	8.03%	0.91%	0.00%
	0.00%	0.00%	0.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	42.26%	44.43%	43.13%	38.23%	38.34%	38.44%	38.52%	49.72%	55.08%	43.14%
No. of Shareholders	18,970	15,511	14,652	14,578	15,859	25,342	23,397	22,439	28,117	39,222

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls